NMS · Financial Statements

LENZ Therapeutics, Inc. (LENZ) Financial Statements

$3.16 NMS: LENZ Market Cap $99.29M

LENZ Therapeutics, Inc. most recently reported annual revenue of $19.0M, a net loss of $82.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

LENZ Therapeutics, Inc.: net profit was positive in 0 of 7 reported years; operating margin moved from -69.9% to -477.5%, a shift of -407.6 percentage points; the most recent year shows a net loss of $82.0M.

Income Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Revenue$0$0$0$15.0M$0$0$19.0M
Operating Expenses$0$14.0M$60.0M$25.0M$72.0M$59.0M$110.0M
Operating Profit$0$-13.0M$-60.0M$-10.0M$-72.0M$-59.0M$-91.0M
Operating Margin0.0%0.0%0.0%-69.9%0.0%0.0%-477.5%
Other Income$0$-55.0M$-10.0M$0$2.0M$9.0M$10.0M
Interest$0$0$0$0$0$0$0
Depreciation$0$0$1.0M$0$0$0$0
Profit Before Tax$0$-68.0M$-71.0M$-10.0M$-70.0M$-50.0M$-82.0M
Tax$0$0$0$-3.3M$260,000$0$-620,000
Net Profit$0$-68.0M$-71.0M$-11.0M$-70.0M$-50.0M$-82.0M
EPS$-0.01$-8.24$-8.54$-12.89$-15.30$-2.34$-2.85
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$5.0M$13.0M$2.0M$2.0M$5.0M
Operating Expenses$20.0M$25.0M$16.0M$14.0M$13.0M$15.0M$17.0M$22.0M$31.0M$40.0M$46.0M$40.0M
Operating Profit$-20.0M$-25.0M$-16.0M$-14.0M$-13.0M$-15.0M$-17.0M$-17.0M$-19.0M$-38.0M$-44.0M$-34.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%-337.1%-151.1%-2422.1%-2321.7%-622.9%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-19.0M$-24.0M$-17.0M$-10.0M$-10.0M$-13.0M$-15.0M$-14.0M$-17.0M$-36.0M$-41.0M$-32.0M
Tax$0$750,000$0$0$0$-10,000$0$-3.5M$0$-10,000$0$-10,000
Net Profit$-19.0M$-24.0M$-17.0M$-10.0M$-10.0M$-13.0M$-15.0M$-15.0M$-17.0M$-36.0M$-41.0M$-32.0M
EPS$-2.75$-2.77$-3.53$-0.40$-0.38$-0.46$-0.53$-0.53$-0.59$-1.16$-1.32$-1.02

Over the 7 years reported for LENZ Therapeutics, Inc., borrowings decreased from $2.0M in 2019 to $1.0M in 2025, cash stood at $25.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 14.33 times.

Balance Sheet — 7 Years (USD millions)

Metric2019202020212022202320242025
Total Assets$0$23.0M$18.0M$47.0M$70.0M$215.0M$306.0M
Current Assets$0$21.0M$18.0M$47.0M$67.0M$212.0M$301.0M
Cash$0$20.0M$18.0M$44.0M$35.0M$20.0M$25.0M
Inventory$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$2.0M
Fixed Assets$0$1.0M$0$0$0$2.0M$2.0M
Capital Work in Progress$0$0$0$0$0$0$0
Investments$0$0$0$0$31.0M$189.0M$267.0M
Other Assets$0$0$0$0$0$0$0
Total Liabilities$2.0M$32.0M$33.0M$71.0M$163.0M$11.0M$22.0M
Current Liabilities$2.0M$32.0M$1.0M$9.0M$19.0M$10.0M$21.0M
Borrowings$2.0M$0$0$0$0$1.0M$1.0M
Other Liabilities$0$32.0M$33.0M$71.0M$163.0M$10.0M$21.0M
Equity$0$0$0$0$0$0$0
Reserves$-2.0M$-10.0M$-14.0M$-24.0M$-93.0M$204.0M$284.0M

For LENZ Therapeutics, Inc., operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $70.0M; free cash flow was positive in 0 of 7 years.

Cash Flow Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Operating Cash Flow$0$-9.0M$-53.0M$-88.0M$-60.0M$-59.0M$-69.0M
Investing Cash Flow$0$-3.0M$-11.0M$-248.0M$-30.0M$-155.0M$-76.0M
Financing Cash Flow$0$0$0$0$-2.0M$119.0M$0
Net Cash Flow$0$20.0M$357.0M$-329.0M$-9.0M$-15.0M$5.0M
Free Cash Flow$0$-10.0M$-59.0M$-95.0M$-60.0M$-60.0M$-70.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.70
FCF Yield-102.32%
Quick Ratio13.31
Interest Coverage—
Return 1Y-85.38%
Return 3Y-43.74%
Return 5Y-94.03%

LENZ Therapeutics, Inc. (LENZ) financials — frequently asked questions

What is LENZ Therapeutics, Inc.'s annual revenue?

LENZ Therapeutics, Inc. (LENZ) reported annual revenue of $19.0M in its most recent fiscal year.

What is LENZ Therapeutics, Inc.'s net profit?

LENZ Therapeutics, Inc. (LENZ) reported a net loss of $82.0M in its most recent fiscal year.

What is LENZ EV/EBITDA?

LENZ Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.70. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
LENZ Overview LENZ Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.